|
Published by: Kalorama Information
Published: Oct. 1, 1995 - 205 Pages Now 50% off the original sale price of $3,250.
Table of Contents
Chapter One: Executive Summary
Introduction
Overview of Vaccines
First-Generation or Traditional Vaccines
Second-Generation Vaccines
Technology Trends
Preventive and Therapeutic Vaccines
Pediatric Vaccines
Adult Vaccines
The United States Vaccines Market
Pediatric Vaccines
Market Size
Adult Vaccines
Market Size
The European Vaccines Market
Pediatric Vaccines
Market Size
Adult Vaccines
Market Size
Chapter Two: Preventive Vaccines
Overview of Vaccines
First-Generation or Traditional Vaccines
Second-Generation Vaccines
Technology Trends
Adjuvants
New Vaccine Product Introductions
Available Products
Pediatric Vaccines
Recommended Vaccine Schedule for Infants
BCG Vaccine
Diphtheria, Tetanus, and Pertussis Vaccines
DTP-HIB Vaccines
Hemophilus Influenza type B Vaccine
Hepatitis B Vaccine
Measles, Mumps, and Rubella Vaccines
Polio Vaccines
Varicella Vaccine
Adult Vaccines
BCG Vaccine
Cholera Vaccine
Hepatitis A Vaccine
Hepatitis B Vaccines
Influenza Vaccine
Japanese Encephalitis Vaccine
Pneumococcal Disease Vaccine
Rabies Vaccine
Typhoid Vaccine
Yellow Fever Vaccine
Vaccines in Development
Disease Targets for Pediatric Vaccines in Development
Acute Infantile Gastroenteritis
DTaP-HIB
DTaP-IPV-HIB
Group A Streptococcus
Group B Streptococcus
Hemophilus Influenzae Type B
Malaria
Meningococcus A, B, and C
Pertussis
Pneumococcal Disease
Polio
Pseudomonas Infections
Respiratory Syncytial Virus
Disease Targets for Adult Vaccines in Development
Cholera
Dengue Fever
Gonorrhea
Group B Streptococcus
Helicobacter pylori
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Hepatitis X
Herpesvirus
Human B19 Parvovirus Vaccine
Influenza
Lyme Disease
Rheumatoid Arthritis
Staphylococcus Aureus Infections
Traveler's Diarrhea
Adjuvants
Chapter Three: Therapeutic Vaccines
AIDS Vaccines
AIDS Statistics
HIV and AIDS in the United States
The Disease
The Epidemic
The Cofactor Debate
The Expanded Definition of AIDS
The Changing HIV-Positive Population
AIDS Vaccines In Development
Types of Vaccines
Phases of Vaccine Trials
gp120 Vaccines
gp160 Vaccines
Other Vaccines
The Market for AIDS Vaccines
A Sobering Note
A Controversial Note
Cancer Vaccines
Current Methods of Treatment
Cancer Vaccines: A New Modality of Care
Antigens: Their Role in Cancer Vaccines
Vaccine Development: Strategies
A Summary of Two Approaches: Low-technology vs. High-technology
The Potential Market for Vaccine Biotherapy/Immunotherapy
Therapeutic Vaccines Currently Being Developed for the Treatment of Cancer
Autologous Tumor Vaccine
Bioengineered Therapeutic Cancer Vaccines: Various Strategies
Cancer Center Studies in the United States: Cancer Vaccine Research
The Near Future for Cancer Vaccines
Herpes Vaccines
Chapter Four: Issues and Trends
Product Introductions, Through 2010
The Pediatric Market
The Emergence of New Diseases and Resurgence of Old Ones
Failure to Immunize and the Reasons For It
Market Drivers
Consolidated Alliances
Vertical Integration
Overseas Launch
Barriers to Entry
Technology Trends
Liposomes
Microspheres
Nanoparticles
Worldwide Trends for Selected Vaccines in Development
DTaP-IPV
Meningococcal A, B and C Vaccines
Pneumococcal Vaccines
The Adult Market
Chapter Five: The United States Vaccines Market
Immunization Programs and Their Effect on Disease
Regulatory Issues
The Vaccines for Children Program
Medicare Reimbursement for Influenza Immunization
The Vaccine Injury Compensation Act of 1988
Pricing Changes
Marketing Strategies
The Biotechnology Industry: An Overview
Government Research in Vaccines
Vaccine Purchasers
Size of the Market
Pediatric Vaccines
Market Size
Pricing
Diphtheria-Tetanus-Pertussis Vaccines
Diphtheria-Tetanus-Acellular Pertussis Vaccines
Hepatitis B Vaccines
Hemophilus Influenzae B Vaccines
Measles-Mumps-Rubella Vaccines
Oral Polio Vaccine
Varicella Vaccine
Adult Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccines
Influenza Vaccines
Rabies Vaccine
Market Leaders
Chapter Six: The European Vaccines Market
Regulatory Issues
European Union
Senior Advisory Group for Biotechnology
Forum for European BioIndustry Coordination
Drug Pricing
Foreign Trade
Patents
Patent Protection in Eastern Europe
Approval Time
Trends in Antiviral Vaccines
Size of the Market
Pediatric Vaccines
Market Size
DTP Vaccines
DTaP Vaccines
Hepatitis B Vaccines
Hemophilus Influenzae B Vaccines
Measles-Mumps-Rubella Vaccines
Oral Polio Vaccines
Varicella Vaccine
Adult Vaccines
Hepatitis A Vaccines
Hepatitis B Vaccines
Influenza Vaccines
Rabies Vaccine
Chapter Seven: Company Profiles
Leading Vaccine Manufacturers
Alpha 1 Biomedicals, Inc.
Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Joint Ventures and Licensing Agreements
The Biocine Company
History and Lines of Business
Financial Information
Products
Research and Development
Biogen, Inc.
History and Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Biomira, Inc.
History and Lines of Business
Financial Information
Product Development Strategy
Research and Development
Corporate Strategies
Cambridge Biotech Corporation
Lines of Business
Financial Information
Research and Development
Corporate Strategies
Genelabs Technologies, Inc.
History and Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Genentech, Inc.
Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
IDEC Pharmaceuticals, Inc.
History And Lines Of Business
Financial Information
Product Development Strategy
Research And Development
Corporate Strategies
Patents
ImClone Systems, Inc.
History and Lines of Business
Financial Information
Product Development Strategy
Research and Development
Corporate Strategies
Patents
The Immune Response Corporation
Lines of Business
Financial Information
Research and Development
Corporate Strategies
Patents
Institut Merieux
History and Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
MedImmune, Inc.
History and Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Merck & Company, Inc.
History and Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
North American Vaccine Inc.
Lines of Business
Financial Information
Products
Corporate Strategies
Repligen Corporation
Lines of Business
Financial Information
Research and Development
Corporate Strategies
Ribi ImmunoChem Research, Inc.
History and Lines of Business
Financial Information
Product Development Strategy
Research & Development
Corporate Strategies
SmithKline Beecham
Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Univax Biologics, Inc.
Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Wyeth-Ayerst Laboratories
History and Lines of Business
Financial Information
Products
Research and Development
Corporate Strategies
Appendix A: Vaccine Products
Pediatric Vaccines
Adult Vaccines
Other Related Products
Appendix B: Company Names and Addresses
Associations and Institutions
AbstractThis report from Kalorama Information analyzes the trends shaping the future of the $2.5 billion vaccine industry with an understandable, comprehensive overview of the technological advances in bioengineering, recombinant DNA research and what it means to the future of disease prevention. Also details the life-saving potential of therapeutic vaccines (theraccines) for treating cancer, AIDS, autoimmune diseases and diabetes. Forecasts sales for those products in development; discusses what role key companies may play in the future war against infectious and chronic diseases.
Get Full Details About This Report >>
|
